These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

908 related articles for article (PubMed ID: 6383322)

  • 1. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes.
    Schorlemmer HU; Bosslet K; Sedlacek HH
    Cancer Res; 1983 Sep; 43(9):4148-53. PubMed ID: 6871856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceleration of age-associated immune decline and mortality by early repeated administration of bestatin to C57BL/6 mice.
    Bruley-Rosset M; Payelle B; Rappaport H
    J Biol Response Mod; 1986 Apr; 5(2):176-90. PubMed ID: 3488372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
    Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
    In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
    Colotta F; Peri G; Villa A; Mantovani A
    J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory and therapeutic properties of bestatin in mice.
    Talmadge JE; Lenz BF; Pennington R; Long C; Phillips H; Schneider M; Tribble H
    Cancer Res; 1986 Sep; 46(9):4505-10. PubMed ID: 2942238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulation by the new synthetic thiazole derivative tiprotimod. 2nd communication: immunopharmacological activity.
    Schorlemmer HU; Dickneite G; Blumbach J; Dürckheimer W; Sedlacek HH
    Arzneimittelforschung; 1989 Sep; 39(9):1085-9. PubMed ID: 2590257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental immunological screening tests on pidotimod.
    Coppi G; Manzardo S
    Arzneimittelforschung; 1994 Dec; 44(12A):1411-6. PubMed ID: 7857333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of natural killer cell cytotoxicity during the graft-versus-host reaction. Relationship between natural killer cell activity, T and B cell activity, and development of histopathological alterations.
    Ghayur T; Seemayer TA; Lapp WS
    Transplantation; 1987 Aug; 44(2):254-60. PubMed ID: 3498241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new antitumor drug with immunomodulating activity, ubenimex (bestatin)].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2385-91. PubMed ID: 3496857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similarities in function between pancreatic tumor cells and macrophages and their inhibition by murine monoclonal antibodies.
    Schorlemmer HU; Bosslet K; Kern HF; Sedlacek HH
    Behring Inst Mitt; 1988 Apr; (82):240-64. PubMed ID: 3408453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Activation and regulation of macrophages induced by inoculation of cryodestroyed tumor cells].
    Tsujino M
    Osaka Daigaku Shigaku Zasshi; 1990 Jun; 35(1):180-205. PubMed ID: 2135404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of impaired immune functions of aged animals by chronic bestatin treatment.
    Bruley-Rosset M; Florentin I; Kiger N; Schulz J; Mathé G
    Immunology; 1979 Sep; 38(1):75-83. PubMed ID: 159863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
    Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
    Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunosuppressive activity of L-leucyl-L-leucine methyl ester: selective ablation of cytotoxic lymphocytes and monocytes.
    Thiele DL; Lipsky PE
    J Immunol; 1986 Feb; 136(3):1038-48. PubMed ID: 2934477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.